Compounded semaglutide with pyridoxine (vitamin B6) is a pharmacy-prepared injectable that combines the GLP-1 receptor agonist semaglutide with pyridoxine in a single formulation. It is prepared by licensed 503A compounding pharmacies or 503B outsourcing facilities for individual patients and is not an FDA-approved drug product.
Among clinics ordering through ScriptLinkRx, compounded semaglutide with B6 is the #2 most-prescribed compounded product, based on cumulative order volume across clinics ordering through ScriptLinkRx as of mid-2026. That volume comes primarily from weight-management, med spa, and metabolic-health practices — and it now sits inside one of the most actively regulated corners of pharmacy compounding. This guide summarizes what prescribers need to know about the formulation, the post-shortage regulatory framework, and how to evaluate a compounding pharmacy partner.
What Compounded Semaglutide with B6 Is
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Pharmacologically, GLP-1 receptor agonists act on receptors involved in glucose-dependent insulin secretion, glucagon regulation, and gastric emptying, and they interact with central pathways associated with appetite signaling. FDA-approved semaglutide products exist for type 2 diabetes and chronic weight management; those approved products are the reference point against which any compounded version is legally measured.
Pyridoxine (vitamin B6) is a water-soluble vitamin involved in amino acid metabolism and neurotransmitter synthesis. In compounded formulations, it is included as an additive alongside the active peptide. It is important to be precise about what the combination is and is not: adding B6 to semaglutide does not create a new approved drug, and the clinical rationale for including the additive in a specific patient's therapy rests with the prescriber, not the pharmacy. FDA has stated that the safety and effectiveness of semaglutide combined with added ingredients such as pyridoxine have not been established.
A compounded semaglutide/B6 injection is therefore best understood as a patient-specific preparation: a licensed pharmacy compounds it pursuant to a prescription that documents why a commercially available, FDA-approved product does not meet that patient's needs.
How Providers Use It in Practice
Several practice types account for most ordering activity in this category:
- Weight-management and metabolic clinics. These practices frequently build medically supervised programs around GLP-1 receptor agonist therapy, and some prescribe compounded semaglutide/B6 formulations when they document a patient-specific clinical reason a compounded preparation is appropriate.
- Med spas operating under physician oversight. Clinics that have added medical weight-management services often source compounded formulations through their supervising prescriber and a licensed pharmacy partner.
- Longevity and preventive-health practices. Some providers in this segment prescribe GLP-1 therapies in the context of broader metabolic-health protocols.
The common thread is individualized prescribing. Because the semaglutide shortage has been resolved (see the regulatory section below), a compounded version generally cannot be a routine substitute for the approved product. Providers who continue to prescribe compounded semaglutide/B6 typically do so for patients with a documented clinical difference — and that documentation is the prescriber's responsibility, made at the individual patient level rather than as a clinic-wide default.
Forms and Combinations Available Through Compounding
Compounding pharmacies serving clinics in this category commonly prepare semaglutide in several presentations:
- Subcutaneous injection (multi-dose vial) — the most frequently ordered form, typically dispensed with syringes for in-clinic or at-home administration under a provider's direction.
- Semaglutide with pyridoxine (B6) — the formulation covered in this guide; the additive distinguishes the preparation from the approved product's formulation, though an additive alone does not automatically satisfy the "essentially a copy" analysis (discussed below).
- Semaglutide with cyanocobalamin (B12) — a closely related additive combination covered in our guide to compounded semaglutide with B12.
- Other additive combinations — some pharmacies formulate semaglutide with L-carnitine or NAD+; the same individualized-justification framework applies.
- Oral and sublingual presentations — semaglutide/pyridoxine is also prepared in capsule form, and semaglutide more broadly in sublingual tablets and suspensions; route changes are subject to the same essentially-a-copy analysis.
The legitimate role of compounding here is patient-specific customization: formulation adjustments a prescriber determines are clinically necessary for an identified patient and that are documented on the prescription. What compounding is not permitted to be — as of July 2026 — is a lower-cost parallel supply chain for a commercially available approved drug.
Regulatory Status and Provider Considerations
This section is date-stamped as of July 2026. The regulatory landscape for compounded GLP-1s has moved quickly, and providers should verify current status before making program decisions.
The shortage is resolved, and the compounding window has closed
On February 21, 2025, FDA issued a declaratory order determining that the shortage of semaglutide injection products was resolved. During the shortage, compounders could prepare versions of semaglutide because a drug on FDA's shortage list is not treated as "commercially available" for purposes of the essentially-a-copy restrictions. With the shortage resolved, that exception no longer applies. FDA's enforcement-discretion transition periods — through April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B outsourcing facilities — have long since expired.
The "essentially a copy" framework now governs
As of July 2026, a 503A pharmacy may compound a semaglutide product only if it is not essentially a copy of the commercially available approved products (marketed as Ozempic and Wegovy, referenced here solely for regulatory context). A compounded preparation avoids that classification when a prescriber determines, and documents on the prescription, that a change — such as a different formulation for an allergy to an excipient, or another patient-specific clinical need — produces a significant difference for that patient. For 503B outsourcing facilities, the analysis is stricter still, because 503B compounding from bulk substances generally requires the substance to appear on FDA's 503B bulks list.
Additives like B6 do not provide blanket justification
FDA has publicly questioned compounded GLP-1 products that add ingredients such as pyridoxine, cyanocobalamin, or L-carnitine, noting that the safety and effectiveness of these combinations have not been established. The practical takeaway for prescribers: the presence of B6 in a formulation does not, by itself, make the product meaningfully different from the approved drug for essentially-a-copy purposes. The individualized clinical justification — why this patient needs this formulation — must come from the prescriber and be documented per patient. Clinics using template language or standing justifications across their patient panel carry meaningful compliance risk.
The 2026 proposed 503B bulks exclusion
On April 30, 2026, FDA announced a proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, concluding it did not identify sufficient evidence of clinical need for outsourcing facilities to compound these drugs from bulk substances. The proposal was published in the Federal Register on May 1, 2026, and the comment period was extended to July 30, 2026. If finalized as proposed, outsourcing facilities would generally be unable to compound semaglutide from bulk API outside of a future shortage, further narrowing the compounded GLP-1 channel. Providers building programs around compounded semaglutide should plan for this contingency now.
Watch the perimeter of the category
Regulatory pressure extends beyond semaglutide. FDA has warned about dosing errors and adverse event reports associated with compounded injectable semaglutide and has issued warning letters to sellers of unapproved GLP-1 products. Investigational compounds are a sharper issue still: retatrutide is not FDA-approved for any indication and is not eligible for compounding at all — see the retatrutide regulatory status fact check. Treat any vendor offering investigational GLP-1s as a red flag for the entire relationship.
Sourcing and Quality: What to Ask a Compounding Pharmacy
Because compounded semaglutide/B6 is a sterile injectable that bypasses FDA premarket review, pharmacy selection is the provider's primary quality control. Questions worth asking any prospective pharmacy partner:
- API source and documentation. Is the semaglutide API sourced from an FDA-registered facility, and will the pharmacy share Certificates of Analysis for both the semaglutide and the pyridoxine? Is the API the base form consistent with the approved product, or a salt form (which FDA has flagged as a concern in compounded GLP-1s)?
- Facility type and standards. Is the preparation compounded under USP <797> sterile-compounding standards (503A) or CGMP conditions (503B)? Ask which chapter revisions the facility has implemented and when it was last inspected.
- Potency and sterility testing. Does the pharmacy perform or contract independent testing for potency, sterility, and endotoxin on finished preparations — and will it share results for the lot you receive?
- Beyond-use dating. What BUD is assigned, and is it supported by stability data for this specific formulation, including the B6 additive, rather than borrowed from a different preparation?
- Essentially-a-copy compliance. Does the pharmacy require documented, patient-specific clinical justification on each prescription, or does it accept blanket language? A pharmacy that doesn't ask is a warning sign.
- State licensure. Is the pharmacy licensed in every state where your patients will receive shipments, including any nonresident pharmacy permits?
Clinics that order compounded medications through platforms like ScriptLinkRx can centralize this diligence — working with vetted, licensed partner pharmacies rather than evaluating each relationship from scratch — but the prescriber's independent judgment on patient-specific justification always remains with the prescriber.
Frequently Asked Questions
Is compounded semaglutide with B6 FDA-approved?
No. Compounded drugs are not FDA-approved and do not undergo premarket review for safety, effectiveness, or quality. FDA-approved semaglutide products exist; compounded versions are distinct preparations made under section 503A or 503B of the FD&C Act and are not equivalent to the approved products.
Can clinics still legally prescribe compounded semaglutide after the shortage resolution?
In narrow circumstances. As of July 2026, the shortage-based allowance is gone, so a compounded semaglutide product must not be essentially a copy of the commercially available approved drug — which generally requires a prescriber-documented, patient-specific clinical difference on each prescription. The pathway also depends on the pharmacy's compounding category and pending actions like the proposed 503B bulks exclusion.
Does adding pyridoxine (B6) make the product legally different from the approved drug?
Not automatically. FDA has questioned additive-containing GLP-1 formulations and has stated the safety and effectiveness of such combinations are not established. The additive is only relevant to the essentially-a-copy analysis if the prescriber determines and documents that it produces a significant clinical difference for the individual patient.
What happens if the 2026 proposed 503B bulks exclusion is finalized?
Outsourcing facilities generally could not compound semaglutide from bulk API absent a future shortage; 503A pharmacies would still be governed by the essentially-a-copy framework. Providers should monitor the Federal Register docket — the comment period runs through July 30, 2026 — and build contingency plans.
How should a clinic vet a pharmacy offering semaglutide/B6?
Ask for Certificates of Analysis for the API, evidence of USP <797> or CGMP compliance, third-party potency/sterility/endotoxin testing on finished lots, formulation-specific stability data supporting the beyond-use date, and licensure in your patients' states. A pharmacy that does not require patient-specific justification on prescriptions is a compliance risk for your clinic as well.
Related Reading
- See where semaglutide with B6 ranks among the most-prescribed compounded medications
- Compounded tirzepatide with B6 — the dual-agonist counterpart operating under the same post-shortage framework
- Compounded semaglutide with B12 — how the cyanocobalamin combination compares
Sources
- FDA Declaratory Order: Resolution of Shortages of Semaglutide Injection Products (February 21, 2025)
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
- FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List (April 30, 2026)
- Federal Register: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B (May 1, 2026)
- Federal Register: Extension of Comment Period (June 26, 2026)
- FDA alert: dosing errors associated with compounded injectable semaglutide products
